An overview of arrhythmias and antiarrhythmic approaches

Douglas P. Zipes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

An Overview of Arrhythmias and Antiarrhythmic Approaches. Although treatment of cardiac arrhythmias has been revolutionized in the past decade, patients with atrial fibrillation (AF) still represent a major challenge. With the graying of the population, AF is increasing in prevalence and is responsible for significant morbidity, mortality, and health care expenditures. Drug therapy will be required for the majority of patients with this disorder. Patients with ventricular tachyarrhythmias represent the other major challenge to the cardiac electrophysiologist. The use of implantable cardioverter-defibrillators (ICDs) has reduced the sudden death mortality to 1% or less per year in patients at risk of dying from a ventricular tachyarrhythmia. Unfortunately, high-risk patients who receive an ICD are only a small proportion of the patients who die suddenly each year. Considering the number of at-risk patients, it is likely that drug therapy will remain the mainstay of treatment of patients with ventricular tachyarrhythmias. Therefore, the major challenge is to recognize patients at risk and treat them with antiarrhythmic drugs to prevent sudden cardiac death. Consequently, it has become clear that we have come to a crossroad with regard to antiarrhythmic drugs. Our knowledge of the molecular biology of cardiac ion channels, electrophysiology, and emerging antiarrhythmic drugs provides us an opportunity to create new pharmacologic stratagems.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalJournal of Cardiovascular Electrophysiology
Volume10
Issue number2
StatePublished - 1999

Fingerprint

Cardiac Arrhythmias
Anti-Arrhythmia Agents
Tachycardia
Implantable Defibrillators
Atrial Fibrillation
Drug Therapy
Mortality
Electrophysiology
Sudden Cardiac Death
Health Expenditures
Sudden Death
Ion Channels
Molecular Biology
Morbidity
Delivery of Health Care
Therapeutics
Population

Keywords

  • Atrial fibrillation
  • Electrophysiologic remodeling
  • Implantable cardioverter- defibrillator
  • Sudden death
  • Sympathetic imaging
  • Tachyarrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

An overview of arrhythmias and antiarrhythmic approaches. / Zipes, Douglas P.

In: Journal of Cardiovascular Electrophysiology, Vol. 10, No. 2, 1999, p. 267-271.

Research output: Contribution to journalArticle

@article{8bfbed0dc2164dc8aefa604b2fa2ea3c,
title = "An overview of arrhythmias and antiarrhythmic approaches",
abstract = "An Overview of Arrhythmias and Antiarrhythmic Approaches. Although treatment of cardiac arrhythmias has been revolutionized in the past decade, patients with atrial fibrillation (AF) still represent a major challenge. With the graying of the population, AF is increasing in prevalence and is responsible for significant morbidity, mortality, and health care expenditures. Drug therapy will be required for the majority of patients with this disorder. Patients with ventricular tachyarrhythmias represent the other major challenge to the cardiac electrophysiologist. The use of implantable cardioverter-defibrillators (ICDs) has reduced the sudden death mortality to 1{\%} or less per year in patients at risk of dying from a ventricular tachyarrhythmia. Unfortunately, high-risk patients who receive an ICD are only a small proportion of the patients who die suddenly each year. Considering the number of at-risk patients, it is likely that drug therapy will remain the mainstay of treatment of patients with ventricular tachyarrhythmias. Therefore, the major challenge is to recognize patients at risk and treat them with antiarrhythmic drugs to prevent sudden cardiac death. Consequently, it has become clear that we have come to a crossroad with regard to antiarrhythmic drugs. Our knowledge of the molecular biology of cardiac ion channels, electrophysiology, and emerging antiarrhythmic drugs provides us an opportunity to create new pharmacologic stratagems.",
keywords = "Atrial fibrillation, Electrophysiologic remodeling, Implantable cardioverter- defibrillator, Sudden death, Sympathetic imaging, Tachyarrhythmias",
author = "Zipes, {Douglas P.}",
year = "1999",
language = "English",
volume = "10",
pages = "267--271",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - An overview of arrhythmias and antiarrhythmic approaches

AU - Zipes, Douglas P.

PY - 1999

Y1 - 1999

N2 - An Overview of Arrhythmias and Antiarrhythmic Approaches. Although treatment of cardiac arrhythmias has been revolutionized in the past decade, patients with atrial fibrillation (AF) still represent a major challenge. With the graying of the population, AF is increasing in prevalence and is responsible for significant morbidity, mortality, and health care expenditures. Drug therapy will be required for the majority of patients with this disorder. Patients with ventricular tachyarrhythmias represent the other major challenge to the cardiac electrophysiologist. The use of implantable cardioverter-defibrillators (ICDs) has reduced the sudden death mortality to 1% or less per year in patients at risk of dying from a ventricular tachyarrhythmia. Unfortunately, high-risk patients who receive an ICD are only a small proportion of the patients who die suddenly each year. Considering the number of at-risk patients, it is likely that drug therapy will remain the mainstay of treatment of patients with ventricular tachyarrhythmias. Therefore, the major challenge is to recognize patients at risk and treat them with antiarrhythmic drugs to prevent sudden cardiac death. Consequently, it has become clear that we have come to a crossroad with regard to antiarrhythmic drugs. Our knowledge of the molecular biology of cardiac ion channels, electrophysiology, and emerging antiarrhythmic drugs provides us an opportunity to create new pharmacologic stratagems.

AB - An Overview of Arrhythmias and Antiarrhythmic Approaches. Although treatment of cardiac arrhythmias has been revolutionized in the past decade, patients with atrial fibrillation (AF) still represent a major challenge. With the graying of the population, AF is increasing in prevalence and is responsible for significant morbidity, mortality, and health care expenditures. Drug therapy will be required for the majority of patients with this disorder. Patients with ventricular tachyarrhythmias represent the other major challenge to the cardiac electrophysiologist. The use of implantable cardioverter-defibrillators (ICDs) has reduced the sudden death mortality to 1% or less per year in patients at risk of dying from a ventricular tachyarrhythmia. Unfortunately, high-risk patients who receive an ICD are only a small proportion of the patients who die suddenly each year. Considering the number of at-risk patients, it is likely that drug therapy will remain the mainstay of treatment of patients with ventricular tachyarrhythmias. Therefore, the major challenge is to recognize patients at risk and treat them with antiarrhythmic drugs to prevent sudden cardiac death. Consequently, it has become clear that we have come to a crossroad with regard to antiarrhythmic drugs. Our knowledge of the molecular biology of cardiac ion channels, electrophysiology, and emerging antiarrhythmic drugs provides us an opportunity to create new pharmacologic stratagems.

KW - Atrial fibrillation

KW - Electrophysiologic remodeling

KW - Implantable cardioverter- defibrillator

KW - Sudden death

KW - Sympathetic imaging

KW - Tachyarrhythmias

UR - http://www.scopus.com/inward/record.url?scp=0033007189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033007189&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 267

EP - 271

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 2

ER -